Wednesday, October 7, 2026
ExploreSearch
Via News
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· March 23, 2026

Snowflake (SNOW) Valuation Check As Project SnowWork Expands Its Enterprise AI Ambitions

View original at finance.yahoo.com
Snowflake (SNOW) Valuation Check As Project SnowWork Expands Its Enterprise AI Ambitions Find winning stocks in any market cycle. Join 7 million investors using Simply Wall St's investing ideas for FREE…
Opening lines of the source · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Snowflake's DCF model fair value is $236.22 per share, implying the stock is trading at a 28.9% discount

    60% confidence

  • Snowflake's fair value is $78.83 per share based on the most followed valuation narrative

    60% confidence

  • Snowflake is a company that is growing fast and holding a lot of cash, while spending remains high and seeing significant increase in customer revenue

    60% confidence

  • Snowflake is 113.1% overvalued based on most popular narrative

    60% confidence

  • The valuation narrative could crack if competitive pressure from Databricks intensifies or if Snowflake's losses and stock based compensation continue to weigh on sentiment

    60% confidence

Data points we hold from this source

Snowflake Inc. · fair value dcf236.22 USD
Snowflake Inc. · fair value narrative78.83 USD
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Obesity and Immunology Readouts, Big Pharma M&A and AI-Designed Drugs Converge Into a Q4 2026 Catalyst Wave
Late-stage data and deal activity are clustering ahead of Q4 2026. Novo Nordisk's CagriSema won Best Abstract at EASD 2026 for its brain and body (fMRI/MRI) data, Lilly showed ADtouch results for EBGLYSS and agreed to buy Merida Biosciences for $2.9B, and Merck's tulisokibart hit its Phase 2b endpoints. A key regulatory catalyst follows: the FDA PDUFA date for the ivonescimab BLA on 2026-11-14. AI-designed rentosertib showing anti-aging effects adds a speculative AI-drug-discovery thread, while QAIAx's microcities trial and QIII pilot (planned 2027-01-01) are peripheral, forecast-only items.
Our read on the data ›
Signals we're tracking
Satellite-Terrestrial Network Integration Acceleration
Increased investment and launches in hybrid satellite-cellular networks across telecom industry; competitive responses from other carriers; regulatory activity around satellite spectrum; expansion of emergency/rural connectivity use cases
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,985
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,985 facts checked against source5,351 source documents archived
Query this data → isubstrate.com
Snowflake (SNOW) Valuation Check As Project SnowWork Expands Its Enterprise AI Ambitions — Source | Via News | ViaNews Market